AKT1/PIK3CA/PTEN
1 EU-approved indication of 1 drug needs a AKT1/PIK3CA/PTEN result, in 1 tumour type, most of them in breast cancer.
Approved indications1
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Breast cancer1 | ||||
Truqap | One or more PIK3CA/AKT1/PTEN-alterations, ER-positive, HER2-negative | + fulvestrant | 2L advanced | Recurrence or progression on or after an endocrine-based regimen; In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a LHRH agonist; for men, administration of LHRH agonist according to current clinical practice standards should be considered |
AKT1/PIK3CA/PTEN by tumour
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Capivasertib (Truqap)
TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen (see section 5.1).